Furazolidone Containing Regimens in Eradication of Helicobacter Pylori

Comparison of Quadruple and Triple Furazolidone Containing Regimens on Eradication of Helicobacter Pylori ,in Patients with Helicobacter pylori Infected Duodenal Ulcer , Gastric Ulcer and/or Erosive Gastrodeudinitis .

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013120715701N1

Enrollment

372

Registered

2013-12-31

Start date

2012-06-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peptic Ulcer Disease(H.Pylori Eradication). Gastric ulcer, Duodenal ulcer, Gastritis,unspecified ,Duodenitis

Interventions

Intervention 1: Intervention group:triple therapy including ,omperazol 20 mg Bid,amoxycillin 1 gr Bid and furazolidone 200 mg Tid , all of them for 10 days. Intervention 2: Intervention group 1:quadra

omperazol 20 mg Bid,amoxycillin 1 gr Bid and bismuth 240 mg Bid ,all of them for 10 days.Metronidazol 500 mg Bid for first 5 days and then furazolidone 200 mg Bid for second 5 days.

Treatment - Drugs

Intervention group:triple therapy including ,omperazol 20 mg Bid,amoxycillin 1 gr Bid and furazolidone 200 mg Tid , all of them for 10 days

Intervention group 1:quadrapl therapy including, omperazol 20 mg Bid,amoxycillin 1gr Bid,bismuth 240 mg Bid and furazolidone 200 mg Bid ,all of them for 10 days

Intervention group 2:quadrapl sequential therapy including

Eligibility

Sex/Gender

All

Age

18 Years to 83 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : Helicobacter pylori infected duodenal ulcer; gastric ulcer;Gastric Erosion ;Deudenal Erosion;Age >18 year old. Exclusion criteria :pregnancy ;lactation ; history of previous H.pylori eradication ; taking antibiotics and/or bismuth and/or non-steroidal anti inflammatory drugs during the previous four weeks; concomitant use of anticoagulant or corticosteroid;consuming substantial amounts of alcohol;,history of gastric surgery; significant underlying disease such as; liver;,renal; pulmonary; cardiac disease and neoplasms ; G6PD deficiency ;history of drug allergy to any medication in this study. .

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Helicobacter.pylori eradication rate. Timepoint: 2 months after the completion of treatment courser. Method of measurement: Urea Breath Test.	—

Secondary

Measure	Time frame
Adverse effect of Drugs. Timepoint: Daily recording during and after the treatment course. Method of measurement: Medical history and record sheet.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarjan Mokhtare

Mazandaran University of Medical Scienses

marjanmokhtare@yahoo.com+98 15122771776

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026